Skip to main content
BC Innovations
Feature Story

LEM-on aid for cancer

How new protein LEM could displace anti-PD-1 and CAR T cell therapies

By Stephen Parmley, Senior Writer

New pathways in immunity are few and far between, but a group at Imperial College London has found one that boosts the immune response tenfold and is controlled by the newly discovered protein LEM. The researchers think the target could become a key player in cancer immunotherapy, and that activating LEM offers big advantages over anti-PD-1 and CAR T cell approaches.

The inventors' first move was to spin out ImmunarT Ltd., a newco that will look for therapies that stimulate or suppress LEM for cancer, chronic viral infections or other diseases.

Okoye, I., et al. "The protein LEM promotes CD8+ T cell immunity through effects on mitochondrial respiration." Science (2015)

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial